Beaten up share price offers an opportunity
06/06/25 -"After incorporating our 2027 projections with double-digit top-line growth due to the upcoming product launches, we have reduced our long-term sales and EBITDA growth estimates to 6% (7% previously). ..."
Pages
47
Language
English
Published on
06/06/25
You may also be interested by these reports :
06/02/26
Q4 ‘25 results exceeded consensus, as Lundbeck met its 2025 guidance. Strong growth for depression treatment Rexulti and migraine medicine Vyepti ...
05/02/26
The hugely discounted pricing announced by Hims & Hers for copycat pill versions of Novo’s semaglutide (for weight loss) seems perplexing, as they ...
05/02/26
The Q4 25 performance exceeded expectations, ensuring that GSK delivered on the higher end of the 2025 guidance. HIV, Respiratory, Immunology and ...
04/02/26
The Q4 performance, even though subdued, ensured that Novartis met the management’s 2025 guidance. Healthy Q4 growth across most key areas was ...